Dare Bioscience, Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. Financial statements are unaudited. Dare is a clinical-stage women’s health biopharmaceutical company with no approved or commercialized products and no product revenue.
Financial performance and position
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $6.20 million | $1.97 million | $14.13 million | $6.17 million |
| Total operating expenses | $7.58 million | $3.42 million | $18.96 million | $10.48 million |
| Net loss | $7.58 million | $3.39 million | $18.96 million | $10.40 million |
| Basic and diluted loss per share | $0.24 | $0.20 | $0.69 | $0.76 |
| Cash used in operating activities | Not stated by quarter | $16.04 million | $9.51 million |
Margins are not meaningful because the company reported no revenue. At September 30, cash and cash equivalents were $5.39 million, total current assets were $6.98 million, current liabilities were $7.96 million, and working capital was in deficit by approximately $1.0 million. Total liabilities were $9.05 million; stockholders’ equity was in deficit by $1.39 million. The company reported an accumulated deficit of $62.99 million.
The company had a $367,000 PPP loan, bearing 1% interest and maturing in April 2022; it applied for full forgiveness, but forgiveness was not assured. A $1.0 million contingent-consideration liability is expected to become payable in the first half of 2021. The $1.0 million Bayer upfront payment remained deferred revenue at quarter-end because the license had not yet become effective.
Changes versus prior comparable periods
- Q3 net loss rose to $7.58 million from $3.39 million, principally as R&D expense increased $4.24 million. Dare attributed the increase mainly to DARE-BV1 and Ovaprene development and DARE-LARC1 preclinical work.
- Nine-month net loss increased to $18.96 million from $10.40 million, while R&D expense rose by $7.96 million. General and administrative expense increased $0.87 million over the nine-month period.
- Nine-month operating cash use increased to $16.04 million from $9.51 million. Financing activities provided $16.68 million, mainly from ATM and equity-line stock sales, warrant exercises, and the PPP loan.
- Cash increased from $4.78 million at December 31, 2019 to $5.39 million at September 30, 2020, despite the operating cash outflow, largely because of financing proceeds.
Business outlook, developments, and risks
- Liquidity and going concern: Management stated that existing cash was insufficient for working capital and other liquidity needs over at least the next 12 months from issuance of the statements. The filing says this raises substantial doubt about the company’s ability to continue as a going concern. Additional capital is required; failure to obtain it could force delays, reductions, or termination of programs, or cessation of operations.
- DARE-BV1: The Phase 3 DARE-BVFREE study enrolled 307 participants. Topline results were anticipated by year-end 2020; if successful, an NDA filing was expected in the first half of 2021. Estimated aggregate costs through NDA filing were approximately $10–12 million.
- Ovaprene: Following positive topline postcoital-test results announced in 2019, the company was preparing an IDE submission and pivotal study. It expected topline pivotal-study data by year-end 2022. Bayer may, in its sole discretion, pay an additional $20 million after reviewing pivotal-trial results to make its U.S. license effective; Bayer may also terminate on 90 days’ notice.
- Sildenafil Cream, 3.6%: The Phase 2b trial’s timing was being evaluated in light of COVID-19 disruptions; topline data were projected for year-end 2021.
- DARE-HRT1 and grants: A Phase 1 study began in Australia in July 2020, with topline data anticipated in the first half of 2021 and estimated study costs of approximately $2.5 million. NIH awarded $300,000 for the initial DARE-FRT1 project phase; potential additional funding of up to approximately $2.0 million is conditional and not assured.
- Spending outlook: Dare expected 2020 expenses, particularly R&D, to be significantly higher than in 2019. Most development spending for the remainder of 2020 and in 2021 was expected to focus on DARE-BV1, Ovaprene, and Sildenafil Cream.
- Subsequent financing and dilution: From October 1 through November 11, 2020, the company reported approximately $4.1 million of net ATM proceeds and approximately $0.4 million of net equity-line proceeds. It sold nearly 4.0 million ATM shares and 400,000 equity-line shares during that interval. Common shares issued and outstanding were 37,990,001 on November 11, compared with 33,602,516 at September 30.
- Key risks: COVID-19 could increase development costs or delay trials, enrollment, supply, and regulatory activity, and could constrain access to capital. Other major risks include clinical failure, regulatory uncertainty, dependence on third parties and collaborators, and further equity issuance and dilution. Dare reported no material pending legal proceedings and no material changes to its other previously disclosed risk factors.
Important facts for investors to verify
- Whether Dare obtained sufficient additional financing after November 11, 2020, and the resulting cash runway and dilution.
- Final DARE-BVFREE Phase 3 results, any FDA feedback, and whether the anticipated NDA timing and $10–12 million cost estimate remained achievable.
- Whether Bayer elected to pay the $20 million Ovaprene fee, and the pivotal-trial design, timeline, and funding responsibilities.
- Whether the PPP loan was forgiven and whether the contingent-consideration payment became due as expected.
- Whether COVID-19 or other operational factors changed clinical timelines, enrollment, development costs, or grant availability.